NeuroSense Therapeutics Ltd.
NRSN
$0.98
$0.011.03%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 685.00K | 1.46M | 390.00K | 1.83M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 1.77M | 3.03M | 2.03M | 3.65M | |
| Operating Income | -1.77M | -3.03M | -2.03M | -3.65M | |
| Income Before Tax | -1.80M | -857.00K | -1.78M | -1.76M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -1.80M | -857.00K | -1.78M | -1.76M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -1.80M | -857.00K | -1.78M | -1.76M | |
| EBIT | -1.77M | -3.03M | -2.03M | -3.65M | |
| EBITDA | -1.77M | -3.02M | -2.03M | -3.65M | |
| EPS Basic | -0.08 | -0.05 | -0.10 | -0.13 | |
| Normalized Basic EPS | -0.05 | -0.03 | -0.06 | -- | |
| EPS Diluted | -0.08 | -0.05 | -0.10 | -0.13 | |
| Normalized Diluted EPS | -0.05 | -0.03 | -0.06 | -- | |
| Average Basic Shares Outstanding | 21.65M | 18.14M | 17.17M | 13.66M | |
| Average Diluted Shares Outstanding | 21.65M | 18.14M | 17.17M | 13.66M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |